Dissemination of clinical data for research has limitations. The most coveted data is richly 13 descriptive at the individual level, but acquiring such granularity comes with significant cost, 14 effort, or time. De-identification of individual records is not foolproof, with potential for privacy 15 breaches, especially for "real-world" data derived from electronic health records. Also, the 16 open data movement has progressed slowly for clinical trials, partly due to concerns about data 17 ownership. Here, reverse engineered virtual patient populations (RE-ViPPs) are described, 18 based on aggregate cross-tabulated categorical data from populations. The method does not 19 require end-user access to individual-level data. Rather, using sequential linear regressions and 20 random number generation, it generates virtual individual patients to comprise populations 21 that, on average, closely resemble the real population in question. The method is validated by 22 29 ViPPs to trials, registries, and health record databases could reduce the cost, time, ownership, 30 and de-identification burdens hindering open data by encouraging dissemination of aggregate, 31 richly cross-tabulated real data that investigators can use to construct virtual patients and make 32 meaningful conclusions.
applying it to aggregated data derived from the seminal SPRINT trial, for which the individual- 23 level data is known. The method yields virtual populations, each with 9361 patients, faithfully 24 mimicking the 9361 real SPRINT participants. Multiple logistic regression on 100 such 25 populations shows that, just as in SPRINT, risk factors with the highest odds ratio for the 26 primary event are, in descending order, past clinical cardiovascular disease, age ≥ 75, chronic 27 kidney disease, high non-HDL, and smoking history. Factors associated with fewer events are 28 female sex and intensive blood pressure treatment (the trial's intervention). Application of RE-Introduction 34 Patient-level data from clinical trials, registries, and the electronic health record (EHR) is the 35 basis for most clinical research. Obtaining and sharing such data can be challenging, and 36 concerns have been raised about cost, effort, patient privacy, and data ownership [1] . Even 37 journals with strong policies to promote data sharing of published papers have suboptimal 38 adherence by authors [2] . Paying the right amount of attention to who requests individual level 39 data, the purpose of the request, the structure and format of the data, and its de-identification 40 to an extent sufficient to eliminate any chance of deducing identity, can be administratively 41 taxing on the source institution, and often those costs are passed on to the requesting 42 investigator [3] [4] [5] . 43 Several entities have taken the initiative to open their data for specific trials and 44 registries, which is a positive step forward. These include a consortium of clinical study 45 sponsors initiating clinicalstudydatarequest.com [6, 7] data in an aggregate fashion at those institutions; they are mostly promoted as tools for cohort 61 identification for planning future requests for individual-level data, but they have potential to 62 be more widely used for research purposes [17] [18] [19] . Beyond informing requests for individual 63 level data, these sources of aggregate data, when provided in a richly cross-tabulated fashion, The starting material for RE-ViPP construction consists of aggregate data cross-tabulated for 101 every pair of factors to be analyzed. The cross-tabulation is created by partitioning the entire 102 population into subgroups by the status of one independent factor and recording, for each 103 subgroup, the prevalence of each of the remaining factors, along with the rate of the 104 dependent variable (Fig 1, Steps 1-2). For SPRINT, this is straightforward, since the individual-105 level data is known. For EHR, registry, and large trial databases, this can be done, without giving 106 investigators access to the individual level data, as long as the database can be queried for 107 multiple factors at a time. 108 To start a RE-ViPP, the exact number of patients with and without the first independent 109 variable is assigned to match the real population (Fig 1, Step 3). In the case of the SPRINT 110 analysis, this was female sex. Then, in those virtual patients with the first factor, the second 111 factor (in SPRINT, this was senior status) was assigned to the exact percentage measured in the 112 real population and the same was done for those virtual patients without the first factor. Thus 113 the status of the first and second chosen factors will match the real population exactly. 114 Starting with the third factor (Fig 1, Step 4), linear regression was performed on the 115 aggregate data using all the previously assigned factors to estimate the chances of a patient 116 7 having the new factor as a function of the previously assigned factors. The β coefficients and y-117 intercept from this linear regression comprise a formula to calculate a probability of having the 118 new factor for each virtual patient (Supplemental Information, Appendix 1). Significant 119 interactions between pairs of factors are checked in the linear regression and included if the 120 interaction β is within a factor of 1000 from the other β coefficients (in SPRINT, no such 121 interactions were found between any pair of the 9 factors). 122 Once the probability (between 0 and 1) of having the new factor is calculated for each 123 virtual patient, a random number (between 0 and 1) is generated for each patient (Fig 1, Step 124 5). If the random number is less than the patient's probability of having the new factor, the 125 patient is assigned as having the new factor. Otherwise, the virtual patient does not. This 126 repeated for each patient. Once all patients are assigned, the process repeats for the next 127 factor to be assigned. After sequentially assigning the status for all the factors for all the virtual 128 patients in the above manner, the outcomes are assigned in the same manner. 129 Once all factors and outcomes have been assigned to all virtual patients, the overall rate 130 of each factor and outcome is measured against the actual population, and the virtual 131 population is only accepted if within a specified tolerance, for all factors, of the actual 132 population. If the rate of any factor is outside this tolerance, the random number generation is 133 repeated for all patients and factors in order to create a new virtual population until a 134 population is found that is within tolerance for all factors (Fig 1, Step 6 ). For this study of 135 SPRINT, the tolerance was set at ±0.25%. One hundred such acceptable populations are 136 generated in this manner. and requires a total of 74,888 random numbers. The tolerance was set at 0.25%, meaning that 158 the prevalence of each factor and the primary event rate all had to be within this absolute 159 percentage from the true rate in SPRINT. If this was not true for a given virtual population, all 160 9361 patients were regenerated until the criterion was met. The "SPRINT RE-ViPP Generator" is 161 available for download (Supporting Information, upon publication). 162 One hundred RE-ViPPs were created in this randomized fashion, constrained by the 163 chosen tolerance (each of these RE-ViPPs is available for download in Supporting Information, 164 upon publication). The rate of each included demographic factor (sex, age≥75, black race), 165 clinical factor (prior/current smoking, highest tertile SBP, non-HDL>160 mg/dL, CKD defined by 166 10 eGFR>60, past history of clinical CVD), trial factor (intensive vs standard BP therapy), and the 167 primary outcome (composite myocardial infarction, other acute coronary syndromes, stroke, 168 heart failure, or cardiovascular death), as required by the design, all adhere very closely to the 169 SPRINT rates (Fig 3) . 170 Also across all subgroups, the prevalence of each demographic and clinical factor in each 171 of the 100 virtual patient populations clusters around the actual rates in SPRINT (Fig 4) . The 172 virtual patient population is randomized well to intensive and standard BP therapy, just as the 173 real SPRINT patients, and primary event rates also match across all subgroups (Fig 4) . It is worth 174 noting that the SPRINT population has higher female and lower senior rates amongst black 175 participants, lower rates of smoking and higher non-HDL amongst women, more frequent CKD 176 amongst seniors, and higher event rates in seniors, those with CKD, those with past clinical 177 CVD, and those randomized to non-intensive treatment. All these features are preserved in all 178 of the virtual patient populations. 179 Beyond subgroup characteristics, however, the RE-ViPPs can be analyzed on the 180 individual level similar to a multivariate analysis performed on real populations. Correlation 181 matrices show no strong correlations between the analyzed factors in the RE-ViPPs, just as in 182 the real SPRINT population (Fig 5) . 183 Multiple logistic regression performed on each of the 100 virtual populations show that 184 the odds ratios (ORs) for each factor approximates the ORs in SPRINT (Fig 6) . The method described here is reminiscent of imputation, the process by which missing 213 data for a variable is replaced by a reasonable prediction, often using regression models, based 214 on the extant values for that variable as a function of the other variables in the dataset [24, 25] . 215 This has perhaps taken its most robust form in multiple imputation of chained equations 216 [26, 27] . The method here is distinct from multiple imputation in several ways, but an analogy 217 would be that every patient's status for all the variables beyond the first two are treated as 218 missing, and they are imputed sequentially based on logistic regression analysis of the 219 percentage distributions in the aggregate data. 220 The current study is meant to serve as a practical proof-of-principle example. Data 221 known at the individual level was used to highlight the method and show that the RE-ViPPs 222 result matches that of the real population. In practice, this method would be most useful in 223 situations when the individual-level data is either impossible or difficult to obtain. These are 224 common situations. In many cases, there are concerns about data ownership or patient privacy 225 [28] . In others, it can also involve excess time, effort, and cost [3, 29] . Still in others, the issue 226 may be one of data standardization, where a study would ideally be done across datasets or 227 platforms, but the data exist in incongruent formats in each platform [30] . Also, the sheer bulk 228 of individual-level data may be prohibitive, particularly when there is a desire to combine data 229 from multiple EHRs across the world. With these applications in mind, the "SPRINT RE-ViPP 230 Generator" is provided in the Supporting Information (upon publication) and can be customized 231 to other sets of aggregate data and variables. Tool does for its large national health survey results [14, 16, 17, 19] . Another approach would be 241 to have the "data owners" provide the richly cross-tabulated results across as many categorical 242 variables as possible as a small static file (like Fig 2) and make it open to interested 243 investigators; this approach would probably be more feasible and require less digital The source material can be created by querying a database of accessible clinical data (Steps 1-2) or be provided by the data owners. Generation of RE-ViPPs (Steps 3-6) relies on assigning variable values to each virtual patient in a sequential manner based on linear regression models, driven by random number generation, and subjected to tolerance limits. Fig 1, Steps 1-2. The primary event rate and the prevalence of nine independent factors are shown for subgroups defined by presence or absence of those same factors. This is the starting material necessary to generate RE-ViPPs.
